On November 13, 2017, the U.S. Department of Transportation (DOT) published a final rule in the Federal Register that amends its drug testing program regulations effective January 1, 2018. Specifically, the final rule added four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone) to the DOT drug testing panel. It also added methylenedioxyamphetamine (MDA) as an initial test analyte and removed the testing for methylenedioxyethylamphetamine (MDEA).

This rule change requires that we amend current versions of the Connecticut Statewide Drug and Alcohol Testing Consortium’s Anti-Drug and Alcohol Misuse Policy to incorporate the following changes:

- Opiates is replaced with Opioids on Page 5 of the current versions of the Connecticut Statewide Drug and Alcohol Testing Consortium’s Anti-Drug and Alcohol Misuse Policy – Controlled Substance Testing pursuant to DOT’s decision to expand the drug test panel as referenced above.

- Opiates is removed and replaced with Opioids in Appendix B: New Employee Training Guide - Testing Procedures FTA Program - FTA Prohibited Drugs (DOT 5-Panel Screen).